High-activity and thermal-stability methionine adenosine transferase mutant and application thereof
Through artificial intelligence assisting in the design of high-energy, thermally stable methionine adenosine transferase mutants, the problem of insufficient enzyme activity and stability in enzyme catalysis method is solved, the production efficiency and product quality of S-adenosine methionine are improved, and the production efficiency and product quality of S-adenosine are achieved. Efficient enzymatic reaction.
Patent Information
- Application Number
- CN202411380687.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-12-06
AI Technical Summary
The existing enzyme catalytic method for industrial production of S-adenosine methionine has problems such as low natural enzyme activity, poor stability, substrate inhibition and product inhibition, resulting in low production efficiency and low product quality.
The structural model of methionine adenosine transferase was constructed using artificial intelligence-assisted computational biological methods, and the highly viable, thermally stable mutant enzyme was designed through virtual mutation screening to improve the affinity and stability of the enzyme and enhance the enantiomer excess rate.
Achieve high vitality and thermally stable methionine adenosine transferase mutant, improves the catalytic efficiency and product quality of S-adenosine methionine, with higher yield per unit time than the prior art, and has biological activity (S)-S-gland The enantiomer excess of the aglymethionine isomers is greater than 92%.
Smart Images

Figure CN119082070A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of enzyme engineering, and in particular to a high-activity, heat-stable methionine adenylyltransferase mutant and application thereof. Background Art
[0002] S-adenosylmethionine (SAM) is a physiologically active molecule that is ubiquitous in organisms. It participates in important biochemical reactions in the body as a methyl donor (transmethylation) and a precursor (transsulfuration) of physiological sulfhydryl compounds (such as cysteine, taurine, glutathione and coenzyme A, etc.). In the human liver, it regulates the fluidity of the hepatocyte membrane by methylating the plasma membrane phospholipids, and the transsulfuration reaction can promote the synthesis of sulfide products in the detoxification process, which helps prevent intrahepatic cholestasis.
[0003] Acid radical ions with larger molecular weight can combine with SAM to form complex salts through electrostatic interaction, reducing the racemization reaction rate of SAM and thus improving its stability. SAM products include two salt forms - adenosylmethionine butanedisulfonate and adenosylmethionine p-toluenesulfonate sulfate:
[0004] The former is used as a medicine in countries such as Italy and China (Simetai, ), its indications include intrahepatic cholestasis before cirrhosis and due to cirrhosis, intrahepatic cholestasis during pregnancy, and the price of pharmaceutical-grade adenosylmethionine butanedisulfonate is about 3 million yuan per ton; the latter is used as a dietary supplement in the United States and other countries for liver protection, relief of joint pain and improvement of mood.
[0005] At present, the industrial production of SAM at home and abroad is mainly based on the fermentation of Saccharomyces cerevisiae, but the metabolic pathway transformation of engineered bacteria is complex, the production cycle is long, and the purification process is complex. The highest yield reported so far is 0.400g / L / h (8.81g / L). SAM produced by microbial fermentation has two isomers at the same time, namely (S)-S-adenosylmethionine and (R)-S-adenosylmethionine, of which only the (S)-S-adenosylmethionine isomer is biologically active, and the (S)-S-isomer accounts for 60.0-75.0% of the total amount of the two isomers, and the inactive (R)-S-isomer accounts for a relatively high proportion (25.0-40.0%).
[0006] Enzyme catalysis has the advantages of short reaction time, high conversion rate, strong stereoselectivity, easy purification, and environmental friendliness, and has gradually attracted attention. There are many isoenzymes of methionine adenosyltransferase (EC2.5.1.6), which are widely present in bacteria, archaea and eukaryotes. Due to the problems of low activity, poor stability, substrate inhibition, product inhibition and other problems of natural enzymes, it is necessary to transform them into industrial enzymes through enzyme engineering technology, such as the "directed evolution of enzymes" technology developed by Professor Frances H. Arnold, the winner of the 2018 Nobel Prize in Chemistry. However, the introduction of random mutations through techniques such as error-prone PCR is essentially an irrational design. The screening of its huge mutant library can often only obtain a few beneficial mutations from tens of thousands of clones, which consumes considerable manpower, material resources and time.
[0007] Methionine adenosyltransferase is a dimerized enzyme that is used as the basic catalytic unit. The substrates are L-methionine (L-Met) and adenosine triphosphate (ATP), and the cofactor magnesium ion (Mg 2+ ), the main product SAM, and the by-products pyrophosphate (PPi) and phosphate (Pi) are all located at the interface of the two monomer enzymes. Their spatial structure is relatively complex, and it is very difficult to obtain co-crystallization of the enzyme and the ligand molecule. Summary of the invention
[0008] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a methionine adenosyltransferase mutant and its application. The present invention is based on a major breakthrough in the application field of artificial intelligence (AI) in computational biology, adopts a rational design strategy of constructing a structural model of the target enzyme and performing virtual mutation screening, and effectively overcomes the screening bottleneck by constructing a "small and fine" high-quality mutant library (hundreds or less). Specifically, starting from the screening of the methionine adenosyltransferase library, the wild-type methionine adenosyltransferase SA2 from Streptomyces avermitilis with the highest activity is used as the chassis enzyme to construct its three-dimensional (3D) structural model, and after the substrate L-methionine and adenosine triphosphate or product S-adenosylmethionine molecules are docked to the enzyme catalytic center, alanine scanning and residue scanning are performed in sequence, and candidate mutants with improved substrate affinity, reduced product affinity or improved stability are selected for further experimental screening, and a series of highly active and thermostable mutant enzymes are obtained, which can be used to produce and prepare S-adenosylmethionine and increase the proportion of (S)-S-adenosylmethionine isomers with biological activity.
[0009] To achieve the above purpose, the technical solution designed by the present invention is as follows:
[0010] The present invention provides a highly active and heat-stable methionine adenyltransferase mutant. Compared with a wild-type methionine adenyltransferase, the mutant has at least one substitution at positions 56, 104, 255, 320, 341 and 366 in its amino acid sequence; wherein the amino acid sequence of the wild-type enzyme is as shown in SEQ ID NO.1.
[0011] Furthermore, compared with the wild-type methionine adenylyltransferase, the amino acid sequence of the mutant contains one or more of the following amino acid residue differences:
[0012] Glutamic acid at position 56 was mutated to glutamine;
[0013] The alanine at position 104 was mutated to lysine;
[0014] The glycine at position 255 was mutated to glutamine;
[0015] The isoleucine at position 320 was mutated to valine;
[0016] Aspartic acid at position 341 was mutated to glycine;
[0017] Alanine at position 366 was mutated to glutamic acid.
[0018] Furthermore, the amino acid sequence of the mutant is any one of the following sequences, specifically as follows:
[0019] The amino acid sequence of the methionine adenylyltransferase mutant E56Q is shown in SEQ ID NO.3, and the glutamic acid at position 56 in the sequence is mutated to glutamine;
[0020] The amino acid sequence of the methionine adenylyltransferase mutant A104K is shown in SEQ ID NO.4, and the alanine at position 104 in the sequence is mutated to lysine;
[0021] The amino acid sequence of the methionine adenylyltransferase mutant G255Q is shown in SEQ ID NO.5, and the glycine at position 255 in the sequence is mutated to glutamine;
[0022] The amino acid sequence of the methionine adenylyltransferase mutant I320V is shown in SEQ ID NO.6, and the isoleucine at position 320 in the sequence is mutated to valine;
[0023] The amino acid sequence of the methionine adenylyltransferase mutant D341G is shown in SEQ ID NO.7, and the aspartic acid at position 341 in the sequence is mutated to glycine;
[0024] The amino acid sequence of the methionine adenylyltransferase mutant A336E is shown in SEQ ID NO.8, and the alanine at position 366 in the sequence is mutated to glutamic acid;
[0025] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E is shown in SEQ ID NO.9, and the glycine at position 255 is mutated to glutamine, and the alanine at position 366 is mutated to glutamic acid;
[0026] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / E56Q is shown in SEQ ID NO. 10, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the glutamic acid at position 56 is mutated to glutamine;
[0027] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / A104K is shown in SEQ ID NO.11, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the alanine at position 104 is mutated to lysine;
[0028] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / I320V is shown in SEQ ID NO.12, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the isoleucine at position 320 is mutated to valine;
[0029] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / D341G is shown in SEQ ID NO. 13, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the aspartic acid at position 341 is mutated to glycine;
[0030] Alternatively, a sequence having an amino acid identity of at least 85% with any one of the sequences shown in SEQ ID No. 3 to 13.
[0031] Furthermore, the activity of the mutant was lower than that of the wild-type methionine adenylyltransferase (2.16×10 4 U / mg) increased by 12.4-45.3%; and the thermal stability of the mutants increased by 14.3-77.7%.
[0032] The present invention also provides a recombinant expression vector for expressing the mutant, wherein the expression vector is pET-28a(+), pET-23a(+), pET-22b(+), pPIC9K, pPICZαA or pGAPZαA.
[0033] The present invention also provides a microbial host cell expressing the mutant or containing the recombinant expression vector.
[0034] Use of any of the following in increasing the expression of methionine adenosyltransferase, wherein:
[0035] (1) the mutants described above;
[0036] (2) the above-mentioned recombinant expression vector;
[0037] (3) The above-mentioned microbial host cells.
[0038] Use of any one of the following in the preparation of S-adenosylmethionine, wherein:
[0039] (1) the mutants described above;
[0040] (2) the above-mentioned recombinant expression vector;
[0041] (3) The above-mentioned microbial host cells.
[0042] The present invention also provides a method for preparing S-adenosylmethionine, which is as follows:
[0043] 1) fermenting, expressing and purifying the above-mentioned microbial host cells to obtain mutant enzymes;
[0044] 2) using the mutant enzyme to carry out an enzymatic reaction, adding 4 to 20% volume of 6M hydrochloric acid to the reaction system to terminate the reaction; obtaining a reaction product, wherein the concentration of S-adenosylmethionine in the reaction product is 2.1 to 3.7 g / L, the yield per unit time is 0.925 to 1.035 g / L / h, and the enantiomeric excess (ee) of the (S)-S-adenosylmethionine isomer is greater than 92%;
[0045] The enzymatic reaction system contains 50-100 mM tris(hydroxymethyl)aminomethane-hydrochloric acid or disodium hydrogen phosphate-potassium dihydrogen phosphate, 20 mM magnesium sulfate or magnesium chloride, 150 mM potassium sulfate or potassium chloride, 10 mM L-methionine, 10 mM adenosine triphosphate, and 0.25-2.5 g / L purified mutant enzyme at a final concentration;
[0046] The reaction conditions are: reaction temperature of 35-50°C, pH of 6.0-8.0, and reaction time of 2-4h.
[0047] The present invention also provides a use of S-adenosylmethionine prepared by the method of claim 8 in the preparation of adenosylmethionine butanedisulfonate or adenosylmethionine p-toluenesulfonate sulfate.
[0048] Beneficial effects of the present invention:
[0049] 1. The present invention rationally designs methionine adenosyltransferase by using AI-assisted computational biology methods to obtain a highly active and thermostable methionine adenosyltransferase mutant. The mutant is expressed and purified to obtain a highly active and thermostable mutant enzyme (with a specific activity of 2.16×10 4 U / mg is increased by 12.4 to 45.3%; at the same time, the stability to heat treatment is increased by 14.3 to 77.7%, thereby improving the catalytic efficiency of preparing S-adenosylmethionine or its salt and the stable reusability of the enzyme.
[0050] The mutant enzyme-catalyzed production of S-adenosylmethionine helps to improve production efficiency, reduce costs and improve product quality: its yield per unit time is 0.925-1.035 g / L / h, which is higher than the highest yield reported; the enantiomeric excess (ee) of the biologically active (S)-S-adenosylmethionine isomer is greater than 92%, which is higher than the current product quality standard.
[0051] The S-adenosylmethionine product has wide application value in the fields of medicines (adenosylmethionine butanedisulfonate), health foods (adenosylmethionine p-toluenesulfonate sulfate), etc., and lays a foundation for industrial scale-up production. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 Comparison of SAM production of methionine adenosyltransferase from different sources;
[0053] Figure 2 Ramachandran analysis of the 3D model of wild-type methionine adenylyltransferase SA2;
[0054] Figure 3 It is a 3D model of the complex between the SA2 wild-type enzyme dimer and the ligand molecule;
[0055] Figure 4 Comparison of the activities of the mutant enzymes of each three-point combination;
[0056] Figure 5 Comparison of the interaction between the mutant enzyme G255Q / A336E / I320V and the SA2 wild-type enzyme and substrate / product ligands;
[0057] Figure 6 Comparison of thermal stability of enzymes with three-point combination mutants;
[0058] Figure 7 The schematic diagram shows the location of the A336E mutation site of the SA2 enzyme and the molecular dynamics simulation of the enzyme protein before and after the mutation;
[0059] Figure 8 LC-MS detection results of S-adenosylmethionine prepared for the mutant enzyme. DETAILED DESCRIPTION
[0060] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand.
[0061] In the following examples, various molecular biological operations not specifically described were performed according to the instructions of the purchased enzymes or kits, or according to the Molecular Cloning Experiment Guide.
[0062] Example 1 Screening of chassis enzymes for methionine adenosyltransferase
[0063] The coding sequences of 12 methionine adenyltransferases from 9 species were collected from the GenBank database as a screening library for candidate chassis enzymes. Through gene synthesis, vector construction, expression purification, and activity determination, the enzymes with the highest activity were screened for use as engineered chassis enzymes, and then rational design of high-activity and high-thermostability mutants was performed. The candidate seed enzymes, species sources, GenBank numbers, and expression vectors are shown in Table 1.
[0064] Table 1 Basic information of each candidate seed enzyme
[0065]
[0066] At 35°C and pH 6-8, the production of SAM produced by methionine adenosyltransferases from different sources was compared horizontally. The 0.5mL reaction system contained 100mM Na2HPO4-KH2PO4 (pH 6.0) or Tris-HCl (pH 7.0 or 8.0) buffer, 20mM MgCl2, 150mM KCl, 10mM L-Met, 10mM ATP, and 125μg purified enzyme. After 3h of reaction, 100μL 6MHCl was added to terminate the reaction. High-performance liquid chromatography (HPLC) was used to detect the SAM production of 12 candidate enzymes, among which the SA2 enzyme showed the highest level under different pH conditions ( Figure 1 ) and was selected as the starting seed enzyme for the subsequent rational design of highly active and thermostable mutants.
[0067] Example 2 Construction of 3D model of wild-type methionine adenylyltransferase of Streptomyces avermitilis
[0068] According to the amino acid sequence ABA39296.1 (402 amino acid residues) of the wild-type methionine adenyltransferase SA2 from Streptomyces avermitilis (hereinafter referred to as SA2 wild-type enzyme), a FASTA format input file (SA2.fasta) was prepared, and the A and B chains of the SA2 enzyme dimer were defined. The 3D structural model of the dimer protein was constructed using AlphaFold2, and the highest-ranked model ranked_0.pdb was selected.
[0069] Command format example:
[0070] bash run_alphafold.sh -d / home / bio / database / -o / home / bio / output / -f / home / bio / input / SA2.fasta-t 2021-11-01-m multimer
[0071] -d: directory path to support database;
[0072] -o: directory path where the results are stored;
[0073] -f: path to the FASTA file containing the sequence;
[0074] -t: maximum template release date;
[0075] -m: Select the preset model configuration (multimer).
[0076] Ramachandran analysis showed that 97.5% of the amino acid residues in the ranked_0 model were located in reasonable regions and 100% of the residues were located in allowed regions ( Figure 2 ), the model quality meets the requirements.
[0077] Example 3 Molecular docking of ligand compounds with wild-type enzyme 3D model
[0078] Maestro was used to prepare the structure of the PDB file of the SA2 wild-type enzyme model, including adding hydrogen atoms, correcting structural errors, generating protonation states, hydrogen bond optimization, energy minimization, etc., and then AutoDockTools was used to prepare the PDBQT file of the protein 3D structure.
[0079] The SDF format structure files of ligands such as ATP (substrate), L-Met (substrate), S-adenosylmethionine (product) and tripolyphosphate (PPPi, intermediate) were downloaded from the PubChem database, converted into PDB format files using MOE, and then the PDBQT files of the small molecule ligand 3D structure were prepared using AutoDockTools.
[0080] AutoDockTools was used to define the macromolecular receptor, small molecule ligand, docking box center and size, and generate a Vina configuration file. Then, AutoDock Vina was run to dock the ligand to the active interface of the SA2 wild-type enzyme (exhaustiveness 1,000). Based on the docking score, the molecular docking model with the best binding conformation (the most negative score) was selected for subsequent analysis or further docking of other ligand molecules. Figure 3 The SA2 enzyme-ligand complex model is shown.
[0081] Example 4 Virtual Alanine Scanning and Residue Scanning
[0082] The SA2 enzyme dimer in the 3D model of the complex obtained in Example 2 was subjected to alanine scanning (Amber10: EHT force field) using MOE, that is, all sites except the key catalytic residues and the original alanine (Ala) were virtually mutated to Ala, with a mutation space of 1120, and sites with affinity changes (dAffinity, ΔΔG) exceeding ±0.1 kcal / mol were screened.
[0083] Based on the sites selected by Ala scanning, virtual saturation mutation based on molecular dynamics simulation (MM) was performed to mutate any selected site to other 19 natural amino acid residues (residue scanning), and the affinity changes of each methionine adenosine transfer mutant enzyme (hereinafter referred to as mutant enzyme) to the ligand molecule were calculated. Combined with the judgment of the rationality of the interaction, mutant enzymes with dAffinity < 0 (Table 2, the more negative the value, the stronger the affinity) were screened for subsequent site-directed mutagenesis experiments, protein expression and high-throughput activity screening.
[0084] Table 2 83 mutants selected by residue scanning and their affinity changes with ATP substrate ligand
[0085]
[0086]
[0087] Example 5 Construction of expression vector of mutant
[0088] 83 pairs of partially overlapping primers for introducing the point mutations shown in Table 1 were designed: each pair of site-directed mutagenesis primers contained a 5' overlapping region and a 3' extension region; except for the mutation site, the primer length was about 25-30 nucleotides, the 5' overlapping region contained 15-20 bases, and the 3' extension region contained at least 10 bases; the mutation site was located in the two primers, respectively, downstream of the overlapping region of the forward primer and at the 5' end of the reverse primer.
[0089] Using the wild-type expression plasmid pET-28a(+)-SA2 of SA2 enzyme as template, 83 groups of site-directed mutagenesis PCR amplifications were performed. Each group of PCR products was treated with DpnI enzyme (NEB) at 37°C for 1h to remove the methylated template plasmid, and then treated with T5 exonuclease, and then chemically transformed into E. coli TOP10 competent cells. After the 83 groups of transformed strains were verified by DNA sequencing, the expression plasmids of each mutant were extracted using the kit of Tiangen Company, and then transformed into the E. coli BL21 (DE3) expression host.
[0090] Example 6 High-throughput screening of mutants
[0091] The amino acid sequence of the wild-type SA2 enzyme is shown in SEQ ID No. 1. After E. coli codon optimization, the nucleotide sequence of its gene sequence (GenBank: DQ191166.1) is shown in SEQ ID No. 2. The nucleotide sequence was commissioned to Wuhan Jinkairui Bioengineering Co., Ltd. for DNA synthesis, and an expression vector pET-28a(+)-SA2 containing an N-terminal His6 tag was constructed.
[0092] 83 mutants (mutants constructed in Example 5) and the expression strain of the wild-type SA2 enzyme were inoculated into a sterile 96-well culture plate (12×7), and 12 wells (1 row) were used for E. coli BL21 (DE3) blank control and reserved for preparing the standard curve. Each well contained 1.2 mL of LB medium, with a kanamycin concentration of 50 μg / mL, and cultured overnight at 37°C and 200 rpm. The next day, the inoculation volume was transferred to 3 parallel new 96-well plates (three biological replicates were set in this example), and the conditions were the same as above and continued to be cultured until OD 600 Reach 0.6-0.8 (take 200 μL of bacterial solution from each well to measure OD 600and record the data), add IPTG to a final concentration of 1mM, and culture at 28℃220rpm for 12h to induce protein expression. Then, the 96-well plate was centrifuged at 4℃3,500rpm for 5min, the culture medium was poured off, 1mL of 50mMTris-HCl buffer (pH8.0) was added to each well to fully resuspend the bacteria, and centrifuged and washed twice. 1mL of reaction solution containing a final concentration of 50mM Tris-HCl (pH 8.0), 10mM L-Met, 10mM ATP, 20mM MgSO4, and 150mM K2SO4 was added, mixed evenly, incubated at 37℃ for 4h, and 40μL of 6M HCl was added to terminate the reaction.
[0093] Under low pH conditions, ammonium molybdate reacts with orthophosphate to generate phosphomolybdic acid, which forms a complex with malachite green, showing strong absorbance at 620 nm, and can accurately measure 0.05 μg of orthophosphate. Take the appropriately diluted above reaction solution and transfer it to a 96-well transparent plate, add malachite green-molybdate reagent (Malachite Green Phosphate Detection Kit, Sigma-Aldrich Company), and measure the absorbance A at 620 nm after reaction incubation. 620 At the same time, a standard curve was prepared using a 0-75 μM Na2HPO4-Na2H2P2O7 concentration gradient solution containing 10 mM ATP. The amount of enzyme required to generate 1 pmol SAM (release 1 pmol orthophosphate ions) in 1 min was defined as 1 enzyme activity unit (U).
[0094] Calculate the A of each well 620 / OD 600 The wild type was taken as 100%, and mutants with the above ratio greater than 100% were selected for rescreening and verification.
[0095] Example 7 Rescreening of mutant enzymes
[0096] Expression and purification of mutant enzymes and SA2 wild-type enzymes: Referring to the culture conditions of Example 5, 200 mL of the induced bacterial solution was centrifuged at 4°C 8,000 rpm for 10 min, and the supernatant was discarded. The bacteria were resuspended in NTA0 buffer (20 mM Tris-HCl, pH 8.0, 0.15 M NaCl), and the bacteria were broken using a high-pressure homogenizer. The supernatant was collected by centrifugation at 4°C 8,000 rpm for 10 min, and transferred to a pre-equilibrated Ni-NTA nickel column, placed in a silent mixer and incubated at 4°C for 1-2 hours, and then the enzyme protein was eluted with NTA0 buffer containing gradient concentrations of imidazole (20, 50, 80, 100, 150, 250, 300 mM). According to the results of SDS-PAGE electrophoresis, the purified eluate was transferred to a 10 kDa cutoff column. Ultra-15 ultrafiltration tube (Merck) was used for ultrafiltration and concentration by centrifugation at 4,000 rpm at 4°C and the buffer was replaced. The protein concentration was quantified using a Bradford protein concentration assay kit (Biyuntian Biotechnology). 50% glycerol was added and the protein was stored in a -80°C refrigerator for later use.
[0097] The enzyme reaction system for the rescreening was based on the 96-well plate initial screening in Example 5, with a volume of 10 mL, an enzyme concentration of 2.5 g / L, and other conditions being the same. The SAM content in the sample was determined using HPLC. Finally, 5 mutant enzymes with higher activity than the wild-type SA2 enzyme were obtained, and their amino acid sequence information included:
[0098] The amino acid sequence of the methionine adenylyltransferase mutant E56Q is shown in SEQ ID NO.3, and the glutamic acid at position 56 in the sequence is mutated to glutamine;
[0099] The amino acid sequence of the methionine adenylyltransferase mutant A104K is shown in SEQ ID NO.4, and the alanine at position 104 in the sequence is mutated to lysine;
[0100] The amino acid sequence of the methionine adenylyltransferase mutant G255Q is shown in SEQ ID NO.5, and the glycine at position 255 in the sequence is mutated to glutamine;
[0101] The amino acid sequence of the methionine adenylyltransferase mutant I320V is shown in SEQ ID NO.6, and the isoleucine at position 320 in the sequence is mutated to valine;
[0102] The amino acid sequence of the methionine adenylyltransferase mutant D341G is shown in SEQ ID NO.7, and the aspartic acid at position 341 in the sequence is mutated to glycine;
[0103] The relative vitality increases were 19.3%, 17.9%, 24.8%, 12.4% and 17.9% respectively.
[0104] Example 8 Design and screening of thermostable mutant enzymes
[0105] Based on the improved activity of the G255Q mutant enzyme, 19 candidate thermostable mutant enzymes were designed by calculation using FireProt v2.0. The mutant enzyme protein was obtained by the expression and purification method of Reference Example 6, and was preheated in a 50°C water bath for 10 minutes before being used for thermostable screening, and then cooled in an ice bath for 10 minutes. After the reaction of the system of Reference Example 6, the SAM content in the sample was determined by HPLC. Among them, the amino acid sequence of the double mutant enzyme is as follows:
[0106] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E is shown in SEQ ID NO.9, and the glycine at position 255 in the sequence is mutated to glutamine, and the alanine at position 366 is mutated to glutamate, and the SAM production of the mutant enzyme G255Q / A336E is 14.3% higher than that of the SA2 wild type.
[0107] Example 9 Site Combination Mutation
[0108] On the basis of the double mutation sites of high activity (G255Q) and thermal stability (A336E) in Example 7, the other four point mutations (E56Q, A104K, I320V and D341G) for improving enzyme activity in Example 6 were introduced. For the four combinations of three-point mutant enzymes, their corresponding amino acid sequences are as follows:
[0109] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / E56Q is shown in SEQ ID NO. 10, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the glutamic acid at position 56 is mutated to glutamine;
[0110] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / A104K is shown in SEQ ID NO.11, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the alanine at position 104 is mutated to lysine;
[0111] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / I320V is shown in SEQ ID NO.12, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the isoleucine at position 320 is mutated to valine;
[0112] The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / D341G is shown in SEQ ID NO.13, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the aspartic acid at position 341 is mutated to glycine.
[0113] The triple-point mutant enzymes of the above four combinations were then screened for high activity and thermal stability.
[0114] like Figure 4As shown, the activity increases of the above four mutant enzymes relative to the SA2 wild-type enzyme were 35.6%, 44.2%, 45.3% and 22.7%, respectively; among them, the activity increases of the triple-point mutant enzymes G255Q / A336E / A104K and G255Q / A336E / I320V relative to the single-point mutant enzyme G255Q were 9.7% and 10.5%, respectively.
[0115] Referring to the method of Example 2, the mutant enzyme G255Q / A336E / I320V was subjected to molecular docking simulation with the substrates L-Met and ATP, and the products SAM and PPPi, respectively.
[0116] like Figure 5 As shown, the G255Q mutation puts the L-Met substrate in a favorable molecular orientation / spatial position: there is a hydrogen bond between the amino group of L-Met and the carbonyl oxygen atom of the glycine Gly255 residue in the wild-type SA2 enzyme, while this hydrogen bond does not exist in the mutant enzyme G255Q, which may be the reason for the different spatial orientations of L-Met in the two complex structures.
[0117] In addition, the I320V mutation weakens steric hindrance and product inhibition and facilitates SAM release: the isoleucine residue Ile320 directly interacts with the methyl group of SAM, which may hinder the release of SAM from the active site, leading to the observed product inhibition; therefore, replacing Ile320 with the smaller valine Val residue may weaken the interaction between them and make it easier for SAM to leave the active site.
[0118] The method of reference Example 7 was used for thermal stability screening, such as Figure 6 As shown, except for the reduced thermal stability of the mutant enzyme G255Q / A336E / D341G, the thermal stability of the mutant enzymes G255Q / A336E / E56Q, G255Q / A336E / A104K and G255Q / A336E / I320V were increased by 52.6%, 36.4% and 77.7% respectively compared with the SA2 wild-type enzyme. It can be seen from the 3D structural model ( Figure 7 ), the 336th residue is located on the surface of the protein, far away from the catalytic center of the enzyme; in the 10ns molecular dynamics simulation, the root mean square deviation (RMSD) of the enzyme protein skeleton after the A336E mutation is lower than that of the wild-type SA2 enzyme, indicating that the A336E mutation makes the overall structure of the enzyme protein more rigid, thereby enhancing its thermal stability.
[0119] Example 10 Application of mutant enzymes in preparing S-adenosylmethionine
[0120] A 10 mL reaction system contained 50 mM Tris-HCl (pH 8.0), 20 mM MgSO4, 150 mM K2SO4, 10 mM L-Met, 10 mM ATP and 2.5 g / L purified SA2 mutant enzyme G255Q / A336E / I320V (each component was added in sequence), and the reaction was carried out at 37°C for 2-4 h. 1 mL of the reaction mixture was taken and 40 μL 6 M HCl was added to terminate the reaction.
[0121] The reaction product was detected using ISQ-EM single quadrupole mass spectrometer (positive ion mode; liquid chromatography column: Poroshell, 250×4.6 mm, 2.7 μm) from Thermo Fisher Scientific, USA. A molecular ion peak with a mass-to-charge ratio of m / z 399.18 was observed at a retention time of 5.28 min ( Figure 8 ), and [SAM+H] + The theoretical m / z value of 399.14 corresponds to 399.14.
[0122] The (S)-S-adenosylmethionine isomer content was determined by HPLC: a LiChrospher 60 RP-select B (250×4 mm, 5 μm) column was used, 3 M ammonium formate (pH 5.0) was used as the mobile phase, the detection wavelength was 260 nm, and the injection temperature was 10°C.
[0123] Calculated by peak area, the S-adenosylmethionine production at 2 and 4 h was 2.1 and 3.7 g / L, respectively, and the unit time yield was 0.925-1.035 g / L / h. The enantiomeric excess (ee) of the (S)-S-adenosylmethionine isomer was greater than 92% [the (S)-S-adenosylmethionine isomer accounted for more than 96% of the total amount of the two isomers of S-adenosylmethionine]; among them,
[0124] Enantiomeric excess (ee) of (S)-S-adenosylmethionine isomer = (S)-S-adenosylmethionine isomer peak area / [(S)-S-adenosylmethionine isomer peak area+(R)-S-adenosylmethionine isomer peak area]×100%.
[0125] The S-adenosylmethionine prepared in this embodiment reacts with butanedisulfonic acid or p-toluenesulfonic acid to form a complex salt, which can be further prepared to obtain butanedisulfonic acid adenosylmethionine or p-toluenesulfonic acid adenosylmethionine sulfate. As a raw material drug, butanedisulfonic acid adenosylmethionine is used to produce enteric-coated tablets and injection preparations, and is suitable for intrahepatic cholestasis before and due to liver cirrhosis, and intrahepatic cholestasis during pregnancy. As a dietary supplement or health food raw material, p-toluenesulfonic acid adenosylmethionine sulfate is used for liver protection, relieving joint pain and improving mood.
[0126] Although the above embodiments have been described in detail, they are only a part of the embodiments of the present invention, not all of them. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all belong to the protection scope of the present invention.
Claims
1. A highly active, thermostable methionine adenylyltransferase mutant, characterized in that: Compared with the wild-type sequence of methionine adenylyltransferase, the mutant has at least one replacement of the amino acids at positions 56, 104, 255, 320, 341 and 366 in its amino acid sequence; wherein the amino acid sequence of the wild-type enzyme is shown in SEQ ID NO.
1.
2. The mutant according to claim 1, characterized in that Compared with the wild-type sequence of methionine adenylyltransferase, the amino acid sequence of the mutant comprises one or more of the following amino acid residue differences: Glutamic acid at position 56 was mutated to glutamine; The alanine at position 104 was mutated to lysine; The glycine at position 255 was mutated to glutamine; The isoleucine at position 320 was mutated to valine; Aspartic acid at position 341 was mutated to glycine; Alanine at position 366 was mutated to glutamic acid.
3. The mutant according to claim 1 or 2, characterized in that The amino acid sequence of the mutant is any one of the following sequences, specifically as follows: The amino acid sequence of the methionine adenylyltransferase mutant E56Q is shown in SEQ ID NO.3, and the glutamic acid at position 56 in the sequence is mutated to glutamine; The amino acid sequence of the methionine adenylyltransferase mutant A104K is shown in SEQ ID NO.4, and the alanine at position 104 in the sequence is mutated to lysine; The amino acid sequence of the methionine adenylyltransferase mutant G255Q is shown in SEQ ID NO.5, and the glycine at position 255 in the sequence is mutated to glutamine; The amino acid sequence of the methionine adenylyltransferase mutant I320V is shown in SEQ ID NO.6, and the isoleucine at position 320 in the sequence is mutated to valine; The amino acid sequence of the methionine adenylyltransferase mutant D341G is shown in SEQ ID NO.7, and the aspartic acid at position 341 in the sequence is mutated to glycine; The amino acid sequence of the methionine adenylyltransferase mutant A336E is shown in SEQ ID NO.8, and the alanine at position 366 in the sequence is mutated to glutamic acid; The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E is shown in SEQ ID NO.9, and the glycine at position 255 is mutated to glutamine, and the alanine at position 366 is mutated to glutamic acid; The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / E56Q is shown in SEQ ID NO. 10, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the glutamic acid at position 56 is mutated to glutamine; The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / A104K is shown in SEQ ID NO.11, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the alanine at position 104 is mutated to lysine; The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / I320V is shown in SEQ ID NO.12, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the isoleucine at position 320 is mutated to valine; The amino acid sequence of the methionine adenylyltransferase mutant G255Q / A336E / D341G is shown in SEQ ID NO. 13, and the glycine at position 255 is mutated to glutamine, the alanine at position 366 is mutated to glutamic acid, and the aspartic acid at position 341 is mutated to glycine; Alternatively, a sequence having an amino acid identity of at least 85% with any one of the sequences shown in SEQ ID No. 3 to 13.
4. The mutant according to claim 3, characterized in that: The activity of the mutant was higher than that of wild-type methionine adenylyltransferase (2.16×10 4 U / mg) increased by 12.4-45.3%; and the thermal stability of the mutants increased by 14.3-77.7%.
5. A recombinant expression vector expressing the mutant according to any one of claims 1 to 3, characterized in that: The expression vector is pET-28a(+), pET-23a(+), pET-22b(+), pPIC9K, pPICZαA or pGAPZαA.
6. A microbial host cell expressing the mutant according to any one of claims 1 to 4 or containing the recombinant expression vector according to claim 5.
7. Use of any one of the following in increasing the expression of methionine adenosyltransferase, characterized in that: (1) The mutant according to any one of claims 1 to 3; (2) The recombinant expression vector according to claim 5; (3) The microbial host cell according to claim 6.
8. Use of any one of the following in the preparation of S-adenosylmethionine, characterized in that: (1) The mutant according to any one of claims 1 to 3; (2) The recombinant expression vector according to claim 5; (3) The microbial host cell according to claim 6.
9. A method for preparing S-adenosylmethionine, characterized in that: The method is as follows: 1) fermenting, expressing and purifying the microbial host cell according to claim 6 to obtain the mutant enzyme; 2) using the mutant enzyme to carry out an enzymatic reaction, adding 4 to 20% volume of 6M hydrochloric acid to the reaction system to terminate the reaction; obtaining a reaction product, wherein the concentration of S-adenosylmethionine in the reaction product is 2.1 to 3.7 g / L, the yield per unit time is 0.925 to 1.035 g / L / h, and the enantiomeric excess of the (S)-S-adenosylmethionine isomer is greater than 92%; The enzymatic reaction system contains 50-100 mM tris(hydroxymethyl)aminomethane-hydrochloric acid or disodium hydrogen phosphate-potassium dihydrogen phosphate, 20 mM magnesium sulfate or magnesium chloride, 150 mM potassium sulfate or potassium chloride, 10 mM L-methionine, 10 mM adenosine triphosphate, and 0.25-2.5 g / L purified mutant enzyme at a final concentration; The reaction conditions are: reaction temperature of 35-50°C, pH of 6.0-8.0, and reaction time of 2-4h.
10. Use of S-adenosylmethionine prepared by the method of claim 8 in the preparation of adenosylmethionine butanedisulfonate or adenosylmethionine p-toluenesulfonate sulfate.
Citation Information
Cited By
High-activity methionine adenosine transferase mutant
CN117384876A
